ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2025 · 107 positions · Total reported value $4.04B · Top-10 concentration 49.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2025 13F filing, ORBIMED ADVISORS LLC disclosed 107 equity positions with a combined reported value of $4.04B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2025 were SVA ($334.00M), EWTX ($330.48M), BSX ($283.80M). By sector, the heaviest allocations are Health Care 83.0%, Industrials 1.6%. Versus the prior quarter, allocation shifted toward Industrials (+0.6pp) and away from Other (-1.0pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q1 2025 were AXSM ($45.10M), SION ($38.75M), TARS ($33.58M).

Of the 23 positions fully exited versus the prior quarter, the largest were SRPT ($117.14M), MRK ($82.56M), BIIB ($77.85M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2025)

  • AXSM AXSOME THERAPEUTICS INC. COM · $45.10M
  • SION SIONNA THERAPEUTICS INC COM · $38.75M
  • TARS TARSUS PHARMACEUTICALS INC COM · $33.58M
  • APLS APELLIS PHARMACEUTICALS INC · $31.32M
  • AMGN AMGEN INC · $13.77M
  • WHWK WHITEHAWK THERAPEUTICS INC · $7.42M
  • TRVI TREVI THERAPEUTICS INC COM · $7.04M
  • KMTS KESTRA MED TECHNOLOGIES LTD · $6.23M

Fully Exited (vs previous quarter)

  • SRPT SAREPTA THERAPEUTICS INC · prev qtr: $117.14M
  • MRK MERCK & CO INC · prev qtr: $82.56M · history
  • BIIB BIOGEN INC · prev qtr: $77.85M
  • MLYS MINERALYS THERAPEUTICS INC COM · prev qtr: $19.84M · history
  • MEDP MEDPACE HLDGS INC · prev qtr: $14.92M
  • ITCI INTRA-CELLULAR THERAPIES INC · prev qtr: $13.61M
  • UHS UNIVERSAL HLTH SVCS INC · prev qtr: $8.97M
  • NMRA NEUMORA THERAPEUTICS INC. COM · prev qtr: $8.53M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 83.0%
Other 15.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.72M $334.00M 8.26%
8.26%
Hold
2 15.02M $330.48M 8.17%
8.17%
Hold
3 2.81M $283.80M 7.02%
7.02%
Reduce
4 337.60K $278.83M 6.89%
6.89%
Hold
5 7.96M $156.64M 3.87%
3.87%
Hold
6 291.00K $144.12M 3.56%
3.56%
Reduce
7 359.20K $133.71M 3.31%
3.31%
Add
8 206.70K $122.34M 3.02%
3.02%
Add
9 1.53M $111.04M 2.75%
2.75%
Add
10 201.20K $105.38M 2.61%
2.61%
Add
11 8.29M $104.27M 2.58%
2.58%
Hold
12 934.64K $103.37M 2.56%
2.56%
Hold
13 346.10K $93.45M 2.31%
2.31%
Reduce
14 662.50K $78.18M 1.93%
1.93%
Add
15 159.90K $77.52M 1.92%
1.92%
Add
16 547.00K $77.35M 1.91%
1.91%
Add
17 2.54M $76.64M 1.90%
1.90%
Reduce
18 1.42M $70.24M 1.74%
1.74%
Reduce
19 129.00K $64.19M 1.59%
1.59%
Add
20 465.00K $62.54M 1.55%
1.55%
Add
21 1.51M $60.65M 1.50%
1.50%
Reduce
22 2.47M $60.54M 1.50%
1.50%
Add
23 3.03M $55.98M 1.38%
1.38%
Hold
24 1.81M $53.52M 1.32%
1.32%
Add
25 3.44M $48.30M 1.19%
1.19%
Add
26 386.70K $45.10M 1.11%
1.11%
New
27 22.36M $42.49M 1.05%
1.05%
Hold
28 3.41M $41.86M 1.03%
1.03%
Hold
29 3.70M $38.75M 0.96%
0.96%
New
30 5.69M $34.84M 0.86%
0.86%
Hold
31 73.11M $34.36M 0.85%
0.85%
Hold
32 653.74K $33.58M 0.83%
0.83%
New
33 999.00K $33.51M 0.83%
0.83%
Hold
34 947.88K $31.80M 0.79%
0.79%
Hold
35 1.43M $31.32M 0.78%
0.78%
New
36 4.00M $29.54M 0.73%
0.73%
Add
37 679.82K $29.43M 0.73%
0.73%
Hold
38 197.50K $22.13M 0.55%
0.55%
Reduce
39 6.94M $22.08M 0.55%
0.55%
Hold
40 7.56M $20.87M 0.52%
0.52%
Hold
41 758.57K $20.48M 0.51%
0.51%
Hold
42 380.00K $20.13M 0.50%
0.50%
Reduce
43 5.78M $20.05M 0.50%
0.50%
Hold
44 2.29M $18.65M 0.46%
0.46%
Hold
45 2.86M $17.26M 0.43%
0.43%
Hold
46 1.75M $16.30M 0.40%
0.40%
Add
47 13.14M $16.03M 0.40%
0.40%
Hold
48 6.06M $15.94M 0.39%
0.39%
Hold
49 2.25M $14.57M 0.36%
0.36%
Reduce
50 1.92M $14.56M 0.36%
0.36%
Reduce

FAQ

What did ORBIMED ADVISORS LLC buy in 2025-Q1?

In its 2025-Q1 13F filing, ORBIMED ADVISORS LLC reported 107 equity positions worth $4.04B in aggregate; its largest disclosed positions were SVA ($334.00M), EWTX ($330.48M), BSX ($283.80M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.04B of long equity holdings across 107 positions as of 2025-Q1. Top-10 holdings account for 49.5% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →